Skip to main content
Collaboration Platform > Oncolytic Herpes Simplex Virus (oHSV) Immunotherapy

Oncolytic Herpes Simplex Virus (oHSV) Immunotherapy

oHSV are engineered viruses that attack cancer cells. They also stimulate the immune system to act against cancer cells.  Timothy P. Cripe, MD, PhD, of Nationwide Children’s Hospital and The Ohio State University has provided a suite of immunotherapy biotechnologies to Open Therapeutics for global scientific collaboration.  This suite of ViruBots have peer review published in vivo results.  Assisted by Drs. Su, Guo, Samy, Krishnamoorthy, Dr. Cripe is developing these ViruBots to target fourteen different cancer types as well as neoplasm.


Our Effort

Open Therapeutics is a major backer of open science and open access efforts.

Open Therapeutics freely provides to science, technology, engineering, and math (STEM) scientists, or another other seriously interested persons, intellectual properties (patents, etc.), grant funding, lab equipment, document development tools, and preprint server in a collaboration platform (Therapoid™).

When the researchers advance the intellectual properties, s/he gains ScienceCoins™; a blockchain-based cryptocurrency.